Mediator is an evolutionarily conserved multi-protein complex which functions as an interface between gene-specific transcription factors and RNA polymerase II ([@bib4]). The complex is composed of three core domains (head, middle, and tail) and a distinct, less strongly associated module (the CDK8 submodule) consisting of four subunits: CDK8, Cyclin C, MED12, and MED13 ([@bib3]; [@bib25]). Mediator can be present in a cell in two different conformations. The smaller, core Mediator (S Mediator) stimulates basal transcription ([@bib21]; [@bib1]). The larger form of Mediator (L Mediator), including CDK8 submodule, associates with decreased gene transcription ([@bib16]). The binding of the submodule causes a structural change within Mediator that prevents interactions with RNA polymerase II ([@bib8]).

Depending on the context, CDK8 submodule itself can act as a negative or positive regulator of transcription. For example, CDK8/Cyclin C is known to phosphorylate the C-terminal domain of RNA polymerase II subunit before the formation of preinitiation complex, which disrupts Mediator--RNA polymerase II interaction and leads to the inhibition of transcription ([@bib13]). CDK8/Cyclin C functions also together with MED12 as a positive regulator of several p53 target genes, including *p21* ([@bib7]). MED12 has a significant role in diverse developmental pathways, such as the nuclear receptor, *Wnt*, and Sonic Hedgehog signalling pathways ([@bib2]; [@bib15]; [@bib30]). It is also required for the activity of the CDK8 submodule ([@bib17]). MED13 connects the CDK8 submodule to Mediator ([@bib16]). In addition, several paralogues of the submodule subunits have been identified ([@bib26]; [@bib5]): MED12L, MED13L, and CDK19, a paralogue of CDK8, which is only conserved in vertebrates ([@bib28]). However, the effects of especially MED12L and MED13L on the function of CDK8 submodule or Mediator remain elusive.

We have previously reported specific somatic mutations in *MED12* exon 2 in the majority of uterine leiomyomas ([@bib23]). All the mutations affected an evolutionary conserved region of the protein. No other frequently mutated genes have been described to date in these lesions ([@bib19]; [@bib20]; [@bib24]) highlighting the role of *MED12* mutations in the genesis of uterine leiomyomas. The tumorigenesis mechanisms related to *MED12* mutations, however, are still unclear. One attractive option is aberrant CDK8 submodule function, but this is not trivial to study. One way of examining the role of the CDK8 submodule in leiomyomagenesis is a thorough mutation analysis of all the subunits in tumours. Detection of even a small number of mutations would provide valuable clues to the uterine leiomyoma biology. Thus, we performed a comprehensive mutation screen covering the coding regions of *CDK8*/*CDK19*, *CCNC*, and *MED13*, components of the CDK8 submodule, in *MED12* mutation-negative uterine leiomyomas. The effort included sequencing of over 4000 DNA fragments.

Materials and methods
=====================

Subjects
--------

The research material contained two series of fresh frozen uterine leiomyomas obtained from the Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Finland. The first series of specimens ('M\' samples) was collected in an anonymous manner from patients according to Finnish laws and regulations by the permission of the director of the health-care unit, and the other series included specimens ('MY\' samples) from patients with an acquired informed consent. None of the samples displayed a mutation in *MED12* exon 2 or in the coding regions of *fumarate hydratase* (*FH*), a gene which has previously been associated with the predisposition to leiomyomas ([@bib27]). Altogether 70 leiomyomas from 46 patients were included in the study. The study was approved by the ethics review board of the Hospital District of Helsinki and Uusimaa, Finland.

Mutation screening
------------------

Mutation screening was carried out by direct sequencing. Oligonucleotide primers were designed with Primer3 software (<http://frodo.wi.mit.edu>) ([Supplementary Table S1](#sup1){ref-type="supplementary-material"}). Sequencing was performed using Big Dye Terminator v3.1 sequencing chemistry (Applied Biosystems, Foster City, CA, USA) on an ABI3730 automatic DNA Sequencer according to the manufacturer\'s instructions. The sequence graphs were analysed manually and with Mutation Surveyor software (SoftGenetics, State College, PA, USA). Mutation analysis was fully successful for *CDK8* exons 2--13 and *CCNC.* For *CDK8* exon 1, *CDK19* and *MED13* 97%, 96%, and 94% of amplicons succeeded, respectively.

Owing to the exceptionally high GC content, the amplification conditions for *CDK8* and *MED13* exon 1 were modified from the Expand Long Template PCR system (Roche Diagnostics, Mannheim, Germany) and carried out in a total of 20 *μ*l reaction mix with 25 ng genomic DNA, 10 m[M]{.smallcaps} dNTP, 10 m[M]{.smallcaps} of each primer, 3U enzyme mix, 10 × BSA, 100% DMSO, and 5 [M]{.smallcaps} GC-melt reagent (Clontech, Palo Alto, CA, USA). After denaturation at 94 °C for 2 min, PCR was performed in 40 cycles of 94 °C for 15 s, 57 °C for 45 s, and 68 °C for 7 min, following final elongation at 68 °C for 10 min.

Somatic status of the observed coding sequence variants was verified by sequencing the corresponding normal tissue DNA each time the frequency of the variant was \<5%. All of the observed common variants had been reported in public databases and were assumed to represent germline variation.

Results
=======

*MED12* mutation-negative uterine leiomyomas did not display somatic mutations in the coding regions of *CDK8*/*CDK19*, *CCNC*, or *MED13* (see [Supplementary Tables S2--S5](#sup1){ref-type="supplementary-material"} for more detailed information). A total of seven coding sequence variants, all in *MED13*, were observed in the study ([Table 1](#tbl1){ref-type="table"}): one non-synonymous variant, c.4823C\>T, p. P1608L, which was predicted to have a neutral effect on protein, and six synonymous variants. Five of these represented already known synonymous changes and one synonymous change c.4998A\>G, p.L1666L had not been previously reported. All the variants were of germline origin.

Discussion
==========

The aim of this study was to search for somatic mutations in the coding sequence of *CDK8*/*CDK19*, *CCNC*, and *MED13* in *MED12* mutation-negative uterine leiomyomas. Altogether 70 uterine leiomyomas were included in the study. No somatic mutations were observed in any of the genes studied. Seven coding sequence variants in *MED13* were identified and all turned out to be present in the germline. These variants are probably neutral polymorphisms. *MED13* haploinsufficiency has recently been suggested to underlie cataract, hearing loss, and semicircular canal dysplasia in one patient ([@bib6]). The loss of one *MED13* copy in the patient was due to an 800 kb deletion involving six genes in the 17q23.2 region.

Both *CDK8* and *CCNC* are frequently dysregulated in a variety of human cancers. CDK8 has been indicated to function as an oncoprotein that promotes the proliferation of both colorectal and melanoma cancer cells ([@bib9]; [@bib14]). Also a role as a tumour suppressor due to a loss or reduction of the protein has been reported, for example, in endometrial cancer ([@bib12]). Similarly, Cyclin C has been shown to have a role both as an oncoprotein and a tumour suppressor ([@bib29]). It is still unclear, what the exact functional consequences of *CDK8* and *CCNC* dysregulation are, and how they are linked to tumorigenesis. CDK19, the paralogue of CDK8, has also been associated with a human disease ([@bib22]). A disruption in *CDK19* caused by an inversion in chromosome 6 has been proposed to lead to microcephaly, congenital retinal fold, and mild mental retardation in a female patient.

In this study, we focused on exon and exon--intron boundaries of *CDK8*/*CDK19*, *CCNC*, and *MED13*. This does not exclude the possibility that intronic variants, changes in regulatory elements, or somatic structural rearrangements in these genes contribute to leiomyomagenesis. Notably, when available gene expression data of 44 *MED12* mutation-negative uterine leiomyomas was compared with that of the corresponding myometrium, nostatistically significant differences in fold change (FC\>2) of *CDK8*/*CDK19*, *CCNC*, and *MED13* were observed (data not shown). According to the literature, on the other hand, somatic structural rearrangements are known to have an impact to the development of *MED12* wild-type lesions. For example, translocations, which lead to *HMGA2* overexpression ([@bib10]; [@bib11]), have been linked to *MED12* mutation-negative leiomyomas ([@bib18]; [@bib20]). The structural rearrangements, however, do not explain the genesis of all *MED12* wild-type lesions.

Taken together, our mutation screen of uterine leiomyomas did not reveal somatic coding mutations in *CDK8*/*CDK19*, *CCNC*, and *MED13*. Notably, no such mutations were observed in *MED12L* or *MED13L* either by analysing whole-genome sequencing data of 34 *MED12* mutation-negative uterine leiomyomas on hand. Thus, *MED12* mutations are likely to lead to specific functional effects not concurrently replicated by mutations in other components of the Mediator kinase module.
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###### Single-nucleotide polymorphisms in the coding regions of *MED13*

  **Gene**    **Nucleotide change**   **Amino-acid change**   **rs-number**  **Number of mutated tumours (/67)**
  ---------- ----------------------- ----------------------- --------------- -------------------------------------
  *MED13*           c.354G\>C                p.L118L           rs78565795    2 (3.0%)
                   c.4275A\>G               p.K1425K           rs76432344    11 (16.4%)
                   c.4320C\>T               p.D1440D            rs671347     67 (100%)
                   c.4823C\>T               p.P1608L           rs151011641   1 (1.5%)
                   c.4848G\>A               p.T1616T            rs2278812    31 (46.3%)
                   c.4998A\>G               p.L1666L                         2 (3.0%)
                   c.6033C\>A               p.I2011I           rs145247799   3 (4.5%)
